title: Targeting Rho associated kinases in leukemia and myeloproliferative neoplasms.
abstract: If ROCKs are going to be targeted as anti-leukemic agents either as a monotherapy or in combination with existing drugs, a better characterization of the relative contribution of ROCK1 and ROCK2 in disease progression is essential.
authors.forename: Raghuveer Singh
authors.initials: RS
authors.lastname: Mali
authors.forename: Reuben
authors.initials: R
authors.lastname: Kapur
mesh_terms: D006801:Humans; D007527:Isoenzymes; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000379:methods; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
chemical_list: D007527:Isoenzymes; D054460:rho-Associated Kinases